PE20161222A1 - Sal de clorhidrato de ((1s,2s,4r)-4-{4-[(1s)-2,3-dihidro-1h-inden-1-ilamino]-7h-pirrolo[2,3-d]pirimidin-7-il}-2-hidroxiciclopentil)metilsulfamato - Google Patents

Sal de clorhidrato de ((1s,2s,4r)-4-{4-[(1s)-2,3-dihidro-1h-inden-1-ilamino]-7h-pirrolo[2,3-d]pirimidin-7-il}-2-hidroxiciclopentil)metilsulfamato

Info

Publication number
PE20161222A1
PE20161222A1 PE2016001604A PE2016001604A PE20161222A1 PE 20161222 A1 PE20161222 A1 PE 20161222A1 PE 2016001604 A PE2016001604 A PE 2016001604A PE 2016001604 A PE2016001604 A PE 2016001604A PE 20161222 A1 PE20161222 A1 PE 20161222A1
Authority
PE
Peru
Prior art keywords
inden
pyrimidin
dihydro
hydroxyciclopentil
methylsulfamate
Prior art date
Application number
PE2016001604A
Other languages
English (en)
Inventor
Ian G Armitage
Marianne Langston
Martin Ian Cooper
Reenu Chopra
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of PE20161222A1 publication Critical patent/PE20161222A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se refiere a un cristal de clorhidrato ((1S,2S,4R)-4-{4-[(1S)-2,3-dihidro-1H-inden-1-ilamino]-7H-pirrolo[2,3-D]pirimidin-7-il}-2-hidroxiciclopentil)metilsulfamato de formula I caracterizado por un patron XRPD que tiene picos de angulos 2(theta): 7.3º, 9.6º, 13.6º, 14.5º, 14.8º, 16.5º, 17.0º, 17.3º, 18.0º, 19.1º, 20.1º, 21.1º, 21.7º, 23.7º ± 0.2 grados. Tambien se refiere a un metodo de obtencion y a una formulacion farmaceutica. Dicho cristal es un inhibidor de enzima activante de E1, siendo util en el tratamiento del cancer
PE2016001604A 2009-05-14 2010-05-13 Sal de clorhidrato de ((1s,2s,4r)-4-{4-[(1s)-2,3-dihidro-1h-inden-1-ilamino]-7h-pirrolo[2,3-d]pirimidin-7-il}-2-hidroxiciclopentil)metilsulfamato PE20161222A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21622109P 2009-05-14 2009-05-14

Publications (1)

Publication Number Publication Date
PE20161222A1 true PE20161222A1 (es) 2016-12-01

Family

ID=42396430

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2016001604A PE20161222A1 (es) 2009-05-14 2010-05-13 Sal de clorhidrato de ((1s,2s,4r)-4-{4-[(1s)-2,3-dihidro-1h-inden-1-ilamino]-7h-pirrolo[2,3-d]pirimidin-7-il}-2-hidroxiciclopentil)metilsulfamato
PE2011001962A PE20120907A1 (es) 2009-05-14 2010-05-13 Sal de clorhidrato de ((1s,2s,4r)-4-{4-[(1s)-2,3-dihidro-1h-inden-1-ilamino]-7h-pirrolo[2,3-d]pirimidin-7-il}-2-hidroxiciclopentil)metilsulfamato

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2011001962A PE20120907A1 (es) 2009-05-14 2010-05-13 Sal de clorhidrato de ((1s,2s,4r)-4-{4-[(1s)-2,3-dihidro-1h-inden-1-ilamino]-7h-pirrolo[2,3-d]pirimidin-7-il}-2-hidroxiciclopentil)metilsulfamato

Country Status (18)

Country Link
US (2) US9187482B2 (es)
EP (2) EP2430026A1 (es)
JP (3) JP2012526808A (es)
KR (2) KR20170102381A (es)
CN (2) CN104016987A (es)
AU (1) AU2010248151B2 (es)
BR (1) BRPI1012142A2 (es)
CA (1) CA2761256C (es)
IL (1) IL216201A (es)
MX (1) MX2011012108A (es)
NZ (2) NZ621128A (es)
PE (2) PE20161222A1 (es)
PH (1) PH12015501925A1 (es)
RU (1) RU2562245C2 (es)
SG (2) SG10201402148SA (es)
UA (1) UA108986C2 (es)
WO (1) WO2010132110A1 (es)
ZA (1) ZA201108347B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
EP2178880B1 (en) 2007-08-02 2017-10-04 Millennium Pharmaceuticals, Inc. Process for the synthesis of e1 activating enzyme inhibitors
RU2562245C2 (ru) 2009-05-14 2015-09-10 Милленниум Фармасьютикалз, Инк. ГИДРОХЛОРИД (1S,2S,4R)-4-{ 4-[(1S)-2,3-ДИГИДРО-1Н-ИНДЕН-1-ИЛАМИНО]-7Н-ПИРРОЛО [2,3-d]ПИРИМИДИН-7-ИЛ} -2-ГИДРОКСИЦИКЛОПЕНТИЛ)МЕТИЛ СУЛЬФАМАТА
WO2012061551A1 (en) * 2010-11-05 2012-05-10 Millennium Pharmaceuticals, Inc. Administration of nedd8-activating enzyme inhibitor
EA031067B1 (ru) * 2011-08-24 2018-11-30 Миллениум Фармасьютикалз, Инк. ИНГИБИТОРЫ Nedd8-АКТИВИРУЮЩЕГО ФЕРМЕНТА
KR101987861B1 (ko) 2011-11-03 2019-06-11 밀레니엄 파머슈티컬스 인코퍼레이티드 Nedd-8 활성화 효소 억제제 및 저메틸화제의 투여
ES2739150T3 (es) * 2012-02-17 2020-01-29 Millennium Pharm Inc Inhibidores de pirazolopirimidinilo de la enzima activadora de ubiquitina
WO2014022744A1 (en) * 2012-08-03 2014-02-06 Millennium Pharmaceuticals, Inc. INDOLE-SUBSTITUTED PYRROLOPYRIMIDINYL INHIBITORS OF Uba6
US10662477B2 (en) 2012-10-01 2020-05-26 Millennium Pharmaceuticals, Inc. Biomarkers and methods to predict response to inhibitors and uses thereof
CA2923752A1 (en) 2013-05-14 2014-11-20 Millennium Pharmaceuticals, Inc. Administration of nedd8-activating enzyme inhibitor and chemotherapeutic agents
US9695154B2 (en) 2013-07-02 2017-07-04 Millennium Pharmaceuticals, Inc. Heteroaryl inhibitors of sumo activating enzyme
EA034119B1 (ru) 2014-07-01 2019-12-30 Милленниум Фармасьютикалз, Инк. Гетероарильные соединения, пригодные в качестве ингибиторов sumo-активирующего фермента
CN106008394B (zh) * 2016-05-23 2018-12-04 中国人民解放军第二军医大学 巯基苯并噻唑酰胺类化合物及其制备与作为药物的用途
WO2019060536A1 (en) * 2017-09-21 2019-03-28 Millennium Pharmaceuticals, Inc. CO-CRYSTALLINE FORMS OF ((1S, 2S, 4R) -4- {4 - [(1S) -2,3-DIHYDRO-1H-INDEN-1-YLAMINO] -7H-PYRROLO [2,3-D] PYRIMIDIN -7-YL} -2-HYDROXYCYCLOPENTYL) METHYLSULFAMATE, THEIR FORMULATIONS AND USES
WO2020176643A1 (en) * 2019-02-26 2020-09-03 Millennium Pharmaceuticals, Inc. Compounds useful as adjuvants
KR20210115680A (ko) 2020-03-16 2021-09-27 서희강 연설용 프롬프터
WO2022112951A1 (en) * 2020-11-25 2022-06-02 Takeda Pharmaceutical Company Limited Solid state forms of hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3622561A (en) 1969-08-18 1971-11-23 Univ Utah Nucleoside sugar esters of sulfamic acid and method for preparation of the same
US4252951A (en) * 1979-10-09 1981-02-24 Eli Lilly And Company Isolation of syn-7-(2-amino-4-thiazolyl)-(methoxyimino)acetamido-3-acetoxymethyl-3-cephem-4-carboxylic acid
JPS62108897A (ja) 1985-11-05 1987-05-20 Rikagaku Kenkyusho アスカマイシン誘導体及びその合成法並びに制癌剤
GB8813148D0 (en) 1988-06-03 1988-07-06 Glaxo Group Ltd Chemical compounds
GB8826205D0 (en) 1988-11-09 1988-12-14 Wellcome Found Heterocyclic compounds
US5864033A (en) 1989-09-15 1999-01-26 Metabasis Therapeutics, Inc. Adenosine kinase inhibitors
US5674998A (en) 1989-09-15 1997-10-07 Gensia Inc. C-4' modified adenosine kinase inhibitors
US5721356A (en) 1989-09-15 1998-02-24 Gensia, Inc. Orally active adenosine kinase inhibitors
US5763596A (en) 1989-09-15 1998-06-09 Metabasis Therapeutics, Inc. C-4' modified adenosine kinase inhibitors
US5726302A (en) 1989-09-15 1998-03-10 Gensia Inc. Water soluble adenosine kinase inhibitors
US5470898A (en) 1993-06-30 1995-11-28 Montell North America Inc. Sorbitol derivatives as nucleators and clarifiers for polyolefins, and polyolefin compositions obtained therewith
GB9325810D0 (en) 1993-12-17 1994-02-23 Zeneca Ltd Herbicidal composition
GB9325809D0 (en) 1993-12-17 1994-02-23 Zeneca Ltd Herbicidal composition
US6210917B1 (en) 1993-12-29 2001-04-03 The Regents Of The University Of California Method for suppressing multiple drug resistance in cancer cells
US5767097A (en) 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
US5973161A (en) 1996-03-18 1999-10-26 The University Of North Carolina At Chapel Hill Enantioselective synthesis of cyclopentenes
US5824657A (en) 1997-03-18 1998-10-20 Cubist Pharmaceuticals, Inc. Aminoacyl sulfamides for the treatment of hyperproliferative disorders
US6734283B1 (en) 1997-12-19 2004-05-11 Millennium Pharmaceuticals, Inc. Human proteins responsible for NEDD8 activation and conjugation
JPH11228446A (ja) 1998-02-16 1999-08-24 Mitsubishi Chemical Corp 抗マラリア剤
JPH11228422A (ja) 1998-02-16 1999-08-24 Mitsubishi Chemical Corp 抗マラリア剤
PT1411954E (pt) 2000-10-18 2011-03-16 Pharmasset Inc Nucleosídeos modificados para o tratamento de infecções virais e proliferação celular anormal
DE60236322D1 (de) 2001-12-07 2010-06-17 Vertex Pharma Verbindungen auf pyrimidin-basis als gsk-3-hemmer
AU2003248708A1 (en) 2002-06-17 2003-12-31 Isis Pharmaceuticals, Inc. Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation
US7915293B2 (en) 2003-05-30 2011-03-29 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
US7338957B2 (en) 2003-08-28 2008-03-04 Irm Llc Compounds and compositions as protein kinase inhibitors
EP1680431A1 (en) 2003-10-17 2006-07-19 Rigel Pharmaceuticals, Inc. Benzothiazole and thiazole'5,5-b!pyridine compositions and their use as ubiquitin ligase inhibitors
EP1730122A2 (en) 2004-03-30 2006-12-13 Taisho Pharmaceutical Co., Ltd Pyrimidine derivatives and methods of treatment related to the use thereof
JP2008503591A (ja) 2004-06-22 2008-02-07 ライジェル ファーマシューティカルズ， インコーポレイテッド ユビキチンリガーゼ阻害剤
JP5048520B2 (ja) 2005-02-04 2012-10-17 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｅ１活性化酵素の阻害剤
CN106008512B (zh) 2006-02-02 2019-03-12 千禧药品公司 E1活化酶抑制剂
WO2008019124A1 (en) * 2006-08-08 2008-02-14 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of e1 activating enzymes
EP2178880B1 (en) * 2007-08-02 2017-10-04 Millennium Pharmaceuticals, Inc. Process for the synthesis of e1 activating enzyme inhibitors
RU2562245C2 (ru) 2009-05-14 2015-09-10 Милленниум Фармасьютикалз, Инк. ГИДРОХЛОРИД (1S,2S,4R)-4-{ 4-[(1S)-2,3-ДИГИДРО-1Н-ИНДЕН-1-ИЛАМИНО]-7Н-ПИРРОЛО [2,3-d]ПИРИМИДИН-7-ИЛ} -2-ГИДРОКСИЦИКЛОПЕНТИЛ)МЕТИЛ СУЛЬФАМАТА
KR101987861B1 (ko) 2011-11-03 2019-06-11 밀레니엄 파머슈티컬스 인코퍼레이티드 Nedd-8 활성화 효소 억제제 및 저메틸화제의 투여
CA2923752A1 (en) 2013-05-14 2014-11-20 Millennium Pharmaceuticals, Inc. Administration of nedd8-activating enzyme inhibitor and chemotherapeutic agents

Also Published As

Publication number Publication date
CA2761256C (en) 2021-01-05
CN104016987A (zh) 2014-09-03
PE20120907A1 (es) 2012-08-18
CN102421780A (zh) 2012-04-18
EP3091020B1 (en) 2020-12-30
PH12015501925A1 (en) 2018-01-22
SG175929A1 (en) 2011-12-29
JP2015096547A (ja) 2015-05-21
ZA201108347B (en) 2014-05-26
AU2010248151B2 (en) 2016-07-14
IL216201A (en) 2015-11-30
EP3091020A3 (en) 2017-01-11
JP2012526808A (ja) 2012-11-01
KR20120024715A (ko) 2012-03-14
NZ596470A (en) 2014-04-30
US20170000792A9 (en) 2017-01-05
AU2010248151A1 (en) 2011-12-01
US20110021544A1 (en) 2011-01-27
CA2761256A1 (en) 2010-11-18
MX2011012108A (es) 2011-12-08
RU2011150826A (ru) 2013-06-20
US9187482B2 (en) 2015-11-17
SG10201402148SA (en) 2014-07-30
BRPI1012142A2 (pt) 2016-03-29
US10016427B2 (en) 2018-07-10
RU2562245C2 (ru) 2015-09-10
WO2010132110A1 (en) 2010-11-18
KR20170102381A (ko) 2017-09-08
UA108986C2 (uk) 2015-07-10
NZ621128A (en) 2015-08-28
JP2017105816A (ja) 2017-06-15
EP2430026A1 (en) 2012-03-21
EP3091020A2 (en) 2016-11-09
IL216201A0 (en) 2012-01-31
US20160030432A1 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
PE20161222A1 (es) Sal de clorhidrato de ((1s,2s,4r)-4-{4-[(1s)-2,3-dihidro-1h-inden-1-ilamino]-7h-pirrolo[2,3-d]pirimidin-7-il}-2-hidroxiciclopentil)metilsulfamato
BR112012032234A2 (pt) "derivados de heteroaril imidazolona como inibidores de jak".
CO7170131A2 (es) Compuestos de heterociclilo
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
SV2011003901A (es) Compuestos de arilo con sustituyentes heterocíclicos como inhibidores de hif
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
EA201101618A1 (ru) Арилпиридины в качестве ингибиторов альдостеронсинтазы
BR112013021537A2 (pt) derivados de tiazolilpenil-benzenosulfonamido como inibidores da quinase
PE20121499A1 (es) Formas cristalinas de 3-(2, 6-dicloro-3, 5-dimetoxi-fenil)-1-{6-4[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
NI201000004A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas.
NI200800175A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento de abuso y adicción de sustancias.
AR087672A1 (es) Forma cristalina del sulfamato de {(1s,2s,4r)-4-[(6-{[(1r,2s)-5-cloro-2-metoxi-2,3-dihidro-1h-inden-1-il]amino}pirimidin-4-il)oxi]-2-hidroxiciclopentil}metilo, composiciones farmaceuticas que la contienen y uso de las mismas para tratar cancer
ECSP14001929A (es) Compuestos heterocíclicos, medicamentos que los contienen, uso de aquellos y proceso para su preparación.
ECSP11010992A (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales
BR112013029999A2 (pt) derivados de tiazol
CL2009000004A1 (es) Forma cristalina de r-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida; composicion farmaceutica que comprende a dicha forma cristalina; y uso para el tratamiento de diabetes o hiperglicemia.
PE20080338A1 (es) 4-[5-(2-amino-etansulfonil)-isoquinolin-7-il]-fenol como inhibidor de akt (proteina cinasa)
BR112012006387A2 (pt) aminas de triazol fundidas como moduladores de p2x7
UY32052A (es) 5-aminopirazoles sustituidos y uso de los mismos
UA113962C2 (xx) Фармацевтична композиція, яка містить апоморфін як активний інгредієнт
DOP2011000064A (es) Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il)metoxicarbonilaminio-metil] benzamida (ms-275)
BR112015011974A8 (pt) derivados de azaquinazolina carboxamida, seus usos e processo para sua produção, medicamento e composição farmacêutica
EA201391524A1 (ru) Производные гликозида и их применение
ECSP12011984A (es) Derivados de sulfonamida heterocíclicos
AR084882A1 (es) Compuesto de 1-azabiciclo[2.2.2]octano y usos para el tratamiento de esquizofrenia

Legal Events

Date Code Title Description
FD Application declared void or lapsed